Today, Servier Pharmaceutics acquired the worldwide rights to BN104, a potential best-in-class precision therapy for AML and ALL, from BioNova Pharmaceuticals.
Ellipsis Health, the pioneer in emotionally intelligent AI for healthcare, today announced the close of its $45 million Series A funding round, led by Salesforce, Khosla Ventures, and CVS Health Ventures. Previous investors, Mitsui Global Investment, Collier, E12, and AME Cloud Ventures, also participated in the round.
Stately Bio, a startup developing cell therapies using an ML-powered live-cell imaging platform, today announced $12 million in seed funding led by AIX Ventures, with participation from Dimension Capital, Foothill Ventures, Village Global, Caffeinated Capital, Mitsui Global Investment, BoxOne Ventures, Axial VC, Jeff Dean (Chief Scientist at Google DeepMind), Jeremy Wertheimer (co-founder of ITA Software), and Tom Berry (co-founder of Carbon Health).
Ensem Therapeutics Inc. (ENSEM), today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for ETX-636, a potential best-in-class novel allosteric pan-mutant-selective PI3Kα inhibitor and degrader, with its first-in-human study anticipated in the second quarter of 2025.
QurAlis Corporation (“QurAlis”) , a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced positive topline data from QurAlis’ Phase 1 proof-of-mechanism (PoM) clinical trial of QRL-101 in healthy volunteers evaluating biomarkers related to amyotrophic lateral sclerosis (ALS) and epilepsy.
